ArticleCancer research2024

Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.

Patricia J Keller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.